This article needs to be updated.(October 2021)
|Date||1 February 2021 – present|
|Cause||COVID-19 pandemic in Kazakhstan|
|Part of a series on the|
COVID-19 vaccination in Kazakhstan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.[ citation needed ]
Following the COVID-19 outbreak in Kazakhstan, the Director General of the National Center for Biotechnology Erlan Ramanqūlov in April 2020 announced the stages on developing the COVID-19 vaccine, stressing that clinical trials usually take up to 10 years to develop and that all verified research process would be cut short due to intense situation in the country, making the vaccine against coronavirus be produced usually faster and would be available to the public within next year and a half.
In May 2020, the Ministry of Education and Science reported that the preclinical trials for the COVID-19 vaccine had begun of which was developed by the employees of the Research Institute of Biological Safety Problems of the Science Committee under the Ministry by the strain of the coronavirus isolated from patients and that the World Health Organization (WHO) had registered the vaccine development.At the cabinet meeting, Education and Science Minister Ashat Aimagambetov announced that five COVID-19 vaccines were being developed and that the preclinical trials would be tested on animals until September 2020, when the clinical stages would begin for humans.
Kazakhstan has created its own COVID-19 vaccination, QazCovid-in, developed by the Research Institute for Biological Safety Problems.On 7 April 2021, the Healthcare Minister Alexey Tsoi announced that the Kazakh government had requested 4 million doses of Russia's Sputnik V vaccine, in addition to 2 million doses already received earlier in 2021, as part of an ongoing vaccination programme alongside QazCovid-in.
In October 2021, the first Kazakh vaccine to protect cats from COVID-19, NARUVAX-C19, was unveiled at the Kazagro/Kazfarm-2021 international exhibition.
Kassym-Jomart Kemelevich Tokayev is a Kazakh politician and diplomat who is currently serving as the President of Kazakhstan since 12 June 2019. He became acting president on 20 March 2019 due to the resignation of Nursultan Nazarbayev, who resigned on 19 March 2019 after 29 years in office.
Askar Uzaqbaiuly Mamin is a Kazakh politician who served as the Prime Minister of Kazakhstan from 2019 to 2022, resigning due to pressure from the 2022 Kazakh Protests. He served as First Deputy Prime Minister from 9 September 2016 to 21 February 2019. Previously he was the President of the Kazakhstan Temir Zholy, the national railway company of Kazakhstan. He also serves as the president of the Kazakhstan Ice Hockey Federation, a position he assumed in 2008.
Karim Qazhymqanuly Massimov is a politician who served as a Prime Minister of Kazakhstan from 10 January 2007 to 24 September 2012 and again from 2 April 2014 to 8 September 2016.
Defender of the Fatherland Day is a national holiday celebrated annually on May 7, commemorating the founding of the Armed Forces of Kazakhstan. The event is marked by military parades, fireworks and ceremonies all around the country. The holiday is perceived in society as "a men’s day" and is considered to be the Kazakh analogue to the International Women’s Day.
Bakhytzhan Abdiruly Sagintayev is a Kazakh politician who was a Prime Minister of Kazakhstan, from 9 September 2016 until his resignation on 21 February 2019. He has since 28 June 2019 served as the Äkim of Almaty until being replaced by Erbolat Dosaev on 31 January 2022 following the 2022 Kazakh unrest which greatly affected the city.
Legislative elections were held in Kazakhstan on 10 January 2021 to elect the members of the Mazhilis. This was the 8th legislative election in Kazakhstan's history since its independence. It coincided with the 2021 local elections. This election marks the first to be held under Kassym-Jomart Tokayev's presidency and the first since 2004 to be held at the normally scheduled date, rather than due to an early dissolution of the Mazhilis.
The COVID-19 pandemic in Russia is part of the ongoing pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Russia on 31 January 2020, when two Chinese citizens in Tyumen (Siberia) and Chita tested positive for the virus, with both cases being contained. Early prevention measures included restricting the border with China and extensive testing. The infection spread from Italy on 2 March, leading to additional measures such as cancelling events, closing schools, theatres, and museums, as well as shutting the border and declaring a non-working period which, after two extensions, lasted until 11 May 2020. By the end of March 2020, the vast majority of federal subjects, including Moscow, had imposed lockdowns. By 17 April 2020, cases had been confirmed in all federal subjects. At the beginning of September 2020, the number of COVID-19 cases in Russia exceeded a million. The number of COVID-19 cases in the country also exceeded two million on 19 November 2020, three million on 26 December 2020, four million on 10 February 2021, five million on 23 May 2021, six million on 20 July 2021, seven million on 5 September 2021, eight million on 18 October 2021, nine million on 13 November 2021 and ten million on 12 December 2021. At the end of 2020, there were nearly 3.2 million COVID-19 cases in Russia. On 3 April 2021, the number of COVID-19 deaths in the country exceeded 100,000. Several months later, on 22 September 2021, the number of COVID-19 deaths in Russia exceeded 200,000. On 20 December 2021, the number of COVID-19 deaths in the country exceeded the number of COVID-19 deaths in Mexico. Two days later, on 22 December 2021, the number of COVID-19 deaths in Russia exceeded 300,000. At the end of 2021, there were nearly 10.5 million cases and nearly 310,000 deaths in the country.
The COVID-19 pandemic in Belarus is part of the ongoing worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Belarus, when the first case of COVID-19 in the country was registered in Minsk on 28 February 2020.
The COVID-19 pandemic in Kazakhstan is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have reached Kazakhstan on 13 March 2020 after two Kazakh citizens in Almaty who were recently returned from Germany. That same day, two more cases were confirmed with one female arriving from Italy in Nur-Sultan and the other from Germany in Almaty as well. Following the outbreak, President Kassym-Jomart Tokayev on 15 March 2020 declared a state of emergency that was set to last until 15 April 2020, but were prolonged to 30 April and 11 May 2020 as in order to curb the transmission of the virus, leading to many notable holidays such as Nowruz and the Victory Day being cancelled. On 19 March 2020, a strict quarantine was placed on the cities of Nur-Sultan and Almaty, where the most cases were occurring. On 30 March, Atyrau and 5 cities in Karaganda Region went under a lockdown.
There are no confirmed cases of COVID-19 in Turkmenistan with the totalitarian government being proactive in censoring relevant information. It is however suspected to have spread in the country unreported; specifics are difficult to ascertain and confirm in absence of independent media.
Alexey Vladimirovich Tsoi is a Kazakh politician of who served as the Minister of Healthcare from June 2020 to December 2021
Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.
EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants.
R-Pharm is an international pharmaceutical company headquartered in Russia. It reached the headlines in 2020 following approval of its drug "Coronavir" as a treatment in cases of mild to moderate COVID-19 infection. It was founded by Alexey Repik in 2001, but has had an increasingly international operations base since, with Japanese Corporation Mitsui & Co., Ltd. acquiring 10% of its shares in 2017.
The COVID-19 vaccination campaign in Russia is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Russia became the first country to begin a mass COVID-19 vaccination programme on 5 December 2020, starting with primarily doctors, medical workers and teachers. In January 2021, this was extended to the entire population.
On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
QazCovid-in, commercially known as QazVac, is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.